Provided by Tiger Fintech (Singapore) Pte. Ltd.

4D Molecular Therapeutics

6.42
+1.9242.67%
Post-market: 6.39-0.0300-0.47%19:59 EDT
Volume:31.68M
Turnover:189.32M
Market Cap:297.40M
PE:-2.02
High:6.69
Open:5.28
Low:4.99
Close:4.50
Loading ...

4D Molecular Therapeutics Announces Positive Results from SPECTRA Clinical Trial for 4D-150 in Diabetic Macular Edema, Aligns with EMA on Phase 3 Pathway

Reuters
·
01 Aug

4D Molecular Therapeutics Announces Promising Interim Results from SPECTRA Phase 2a Trial for Diabetic Macular Edema at ASRS 2025

Reuters
·
24 Jul

4D Molecular Therapeutics Announces Inducement Grants Under 2025 Employment Award Plan

Reuters
·
12 Jul

Optimistic Buy Rating for 4D Molecular Therapeutics Amid Strategic Advancements and Market Interest

TIPRANKS
·
04 Jul

4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
03 Jul

4D Molecular Therapeutics Announces Resignation of Chief Financial and Business Officer Uneek Mehra Effective July 2025

Reuters
·
03 Jul

4D Molecular Therapeutics Accelerates 4D-150 Phase 3 Program for Wet AMD, Streamlines Operations for Late-Stage Pipeline Focus

Reuters
·
03 Jul

4D Molecular Therapeutics Inc. Conducted Annual Stockholders Meeting Virtually

Reuters
·
21 Jun

4D Molecular Therapeutics Inc. Set to Participate in Jefferies and Goldman Sachs Global Healthcare Conferences

Reuters
·
28 May

4D Molecular Therapeutics Inc. Announces New Employment Inducement Grants with 31,800 RSUs for Non-Executive Employees

Reuters
·
17 May

Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating

MT Newswires Live
·
12 May

4D Molecular Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
09 May

RBC Cuts Price Target on 4D Molecular Therapeutics to $26 From $35, Keeps Outperform, Speculative Risk

MT Newswires Live
·
09 May

4D Molecular price target lowered to $38 from $45 at Barclays

TIPRANKS
·
09 May

4D Molecular Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

4D Molecular Therapeutics Q1 EPS $0.86 Beats $(0.83) Estimate, Sales $14.00K Miss $382.57K Estimate

Benzinga
·
09 May

4D Molecular Therapeutics Reports Q1 2025 Financial Results; $458 Million Cash Reserves, No Additional Capital Needed Until 2028

Reuters
·
09 May

4D Molecular Therapeutics Inc. to Participate in RBC Capital Markets 2025 Global Healthcare Conference

Reuters
·
05 May

4D Molecular Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview

Reuters
·
05 May

4D Molecular's Macular Edema Treatment Gets Regenerative Medicine Designation from FDA

MT Newswires Live
·
01 May